Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 631

1.

Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance.

de Klerk DJ, Honeywell RJ, Jansen G, Peters GJ.

Cancers (Basel). 2018 Dec 10;10(12). pii: E503. doi: 10.3390/cancers10120503. Review.

PMID:
30544701
2.

Targeting the ribosome biogenesis key molecule fibrillarin to avoid chemoresistance.

El Hassouni B, Sarkisjan D, Vos JC, Giovannetti E, Peters GJ.

Curr Med Chem. 2018 Dec 3. doi: 10.2174/0929867326666181203133332. [Epub ahead of print]

PMID:
30501594
3.

Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study.

Tibaldi C, Camerini A, Tiseo M, Mazzoni F, Barbieri F, Vittimberga I, Brighenti M, Boni L, Baldini E, Gilli A, Honeywell R, Chartoire M, Peters GJ, Giovannetti E; Italian Oncological Group of Clinical Research (GOIRC).

Br J Cancer. 2018 Nov;119(11):1326-1331. doi: 10.1038/s41416-018-0307-3. Epub 2018 Nov 8.

PMID:
30405211
4.

Proton-coupled folate transporter as a biomarker of outcome to treatment for pleural mesothelioma.

Petri GL, Cascioferro S, Parrino B, Peters GJ, Diana P, Giovannetti E.

Pharmacogenomics. 2018 Jul 1;19(10):811-814. doi: 10.2217/pgs-2018-0071. Epub 2018 Jun 19. No abstract available.

5.

Aminopeptidase antibodies in mesothelioma: new wine deserves new sacks.

van Meerbeeck JP, Jansen G, Giovannetti E, Peters GJ.

Eur Respir J. 2018 May 24;51(5). pii: 1800817. doi: 10.1183/13993003.00817-2018. Print 2018 May. No abstract available.

PMID:
29794125
6.

Antipyrimidine effects of five different pyrimidine de novo synthesis inhibitors in three head and neck cancer cell lines.

Peters GJ.

Nucleosides Nucleotides Nucleic Acids. 2018;37(6):329-339. doi: 10.1080/15257770.2018.1460479. Epub 2018 May 3.

PMID:
29723133
7.

High inter-individual variability of serum xanthine oxidoreductase activity in IBD patients.

Meijer B, Seinen ML, Hosman T, Linskens RK, Kneppelhout JK, Peters GJ, Mulder CJ, van Bodegraven AA, de Boer NK.

Nucleosides Nucleotides Nucleic Acids. 2018;37(6):317-323. doi: 10.1080/15257770.2018.1460477. Epub 2018 May 3.

PMID:
29723116
8.

Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer.

van Zweeden AA, van Groeningen CJ, Honeywell RJ, Giovannetti E, Ruijter R, Smorenburg CH, Giaccone G, Verheul HMW, Peters GJ, van der Vliet HJ.

Cancer Chemother Pharmacol. 2018 Jul;82(1):39-48. doi: 10.1007/s00280-018-3588-6. Epub 2018 Apr 25.

9.

5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer.

Toffalorio F, Santarpia M, Radice D, Jaramillo CA, Spitaleri G, Manzotti M, Catania C, Jordheim LP, Pelosi G, Peters GJ, Tibaldi C, Funel N, Spaggiari L, de Braud F, De Pas T, Giovannetti E.

Oncotarget. 2018 Feb 16;9(23):16437-16450. doi: 10.18632/oncotarget.24505. eCollection 2018 Mar 27.

10.

Elucidation of chemosensitization effect of acridones in cancer cell lines: Combined pharmacophore modeling, 3D QSAR, and molecular dynamics studies.

Gade DR, Makkapati A, Yarlagadda RB, Peters GJ, Sastry BS, Rajendra Prasad VVS.

Comput Biol Chem. 2018 Jun;74:63-75. doi: 10.1016/j.compbiolchem.2018.02.014. Epub 2018 Feb 24.

PMID:
29547875
11.

Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide.

Oerlemans R, Berkers CR, Assaraf YG, Scheffer GL, Peters GJ, Verbrugge SE, Cloos J, Slootstra J, Meloen RH, Shoemaker RH, Dijkmans BAC, Scheper RJ, Ovaa H, Jansen G.

Invest New Drugs. 2018 Oct;36(5):797-809. doi: 10.1007/s10637-018-0569-x. Epub 2018 Feb 14.

12.

Cellular pharmacology studies of anticancer agents: recommendations from the EORTC-PAMM group.

Perego P, Hempel G, Linder S, Bradshaw TD, Larsen AK, Peters GJ, Phillips RM; EORTC PAMM Group.

Cancer Chemother Pharmacol. 2018 Mar;81(3):427-441. doi: 10.1007/s00280-017-3502-7. Epub 2017 Dec 28. Review.

PMID:
29285635
13.

Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib.

Muller IB, de Langen AJ, Giovannetti E, Peters GJ.

Onco Targets Ther. 2017 Sep 13;10:4535-4541. doi: 10.2147/OTT.S109493. eCollection 2017. Review.

14.

Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools.

Giovannetti E, Zucali PA, Assaraf YG, Funel N, Gemelli M, Stark M, Thunnissen E, Hou Z, Muller IB, Struys EA, Perrino M, Jansen G, Matherly LH, Peters GJ.

Ann Oncol. 2017 Nov 1;28(11):2725-2732. doi: 10.1093/annonc/mdx499.

15.

The potential of multi-compound nanoparticles to bypass drug resistance in cancer.

Da Silva CG, Peters GJ, Ossendorp F, Cruz LJ.

Cancer Chemother Pharmacol. 2017 Nov;80(5):881-894. doi: 10.1007/s00280-017-3427-1. Epub 2017 Sep 8. Review.

16.

Acridone-pyrimidine hybrids- design, synthesis, cytotoxicity studies in resistant and sensitive cancer cells and molecular docking studies.

Murahari M, Prakash KV, Peters GJ, Mayur YC.

Eur J Med Chem. 2017 Oct 20;139:961-981. doi: 10.1016/j.ejmech.2017.08.023. Epub 2017 Aug 12.

PMID:
28886509
17.

Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN.

Cavazzoni A, La Monica S, Alfieri R, Ravelli A, Van Der Steen N, Sciarrillo R, Madeddu D, Lagrasta CAM, Quaini F, Bonelli M, Fumarola C, Cretella D, Digiacomo G, Tiseo M, Peters GJ, Ardizzoni A, Petronini PG, Giovannetti E.

Oncotarget. 2017 May 23;8(32):53068-53083. doi: 10.18632/oncotarget.18087. eCollection 2017 Aug 8.

18.

A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer.

Coppola S, Carnevale I, Danen EHJ, Peters GJ, Schmidt T, Assaraf YG, Giovannetti E.

Drug Resist Updat. 2017 Mar;31:43-51. doi: 10.1016/j.drup.2017.07.001. Epub 2017 Jul 24. Review.

PMID:
28867243
19.

Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer.

Lam SW, van der Noort V, van der Straaten T, Honkoop AH, Peters GJ, Guchelaar HJ, Boven E.

Pharmacol Res. 2018 Feb;128:122-129. doi: 10.1016/j.phrs.2017.08.005. Epub 2017 Aug 18.

PMID:
28827188
20.

Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC.

Van Der Steen N, Mentens Y, Ramael M, Leon LG, Germonpré P, Ferri J, Gandara DR, Giovannetti E, Peters GJ, Pauwels P, Rolfo C.

Clin Lung Cancer. 2018 Jan;19(1):35-41. doi: 10.1016/j.cllc.2017.06.010. Epub 2017 Jul 6. Review.

PMID:
28757336
21.

Resistance Mechanisms to AZD9291 and Rociletinib-Letter.

Van Der Steen N, Rolfo C, Pauwels P, de Langen AJ, Peters GJ, Giovannetti E.

Clin Cancer Res. 2017 Jul 15;23(14):3966. doi: 10.1158/1078-0432.CCR-17-0167. No abstract available.

22.

Efficacy, pharmacokinetic and pharmacodynamic evaluation of apaziquone in the treatment of non-muscle invasive bladder cancer.

Phillips RM, Hendriks HR, Sweeney JB, Reddy G, Peters GJ.

Expert Opin Drug Metab Toxicol. 2017 Jul;13(7):783-791. doi: 10.1080/17425255.2017.1341490. Epub 2017 Jul 3. Review.

PMID:
28637373
23.

Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds initiative.

Hendriks HR, Govaerts AS, Fichtner I, Burtles S, Westwell AD, Peters GJ.

Br J Cancer. 2017 Jul 11;117(2):195-202. doi: 10.1038/bjc.2017.167. Epub 2017 Jun 13.

24.

Pharmacological factors affecting accumulation of gemcitabine's active metabolite, gemcitabine triphosphate.

Rizzuto I, Ghazaly E, Peters GJ.

Pharmacogenomics. 2017 Jun;18(9):911-925. doi: 10.2217/pgs-2017-0034. Epub 2017 Jun 8. Review.

PMID:
28594276
25.

Rapid Homogeneous Immunoassay to Quantify Gemcitabine in Plasma for Therapeutic Drug Monitoring.

Kozo D, Ross MW, Jarrah J, Barrett M, Harney RL, Courtney JB, Baburina I, Holleran JL, Beumer JH, Peters GJ, Honeywell RJ, Salamone SJ.

Ther Drug Monit. 2017 Jun;39(3):235-242. doi: 10.1097/FTD.0000000000000402.

26.

Molecular mechanism underlying the pharmacological interactions of the protein kinase C-β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells.

Steen NV, Potze L, Giovannetti E, Cavazzoni A, Ruijtenbeek R, Rolfo C, Pauwels P, Peters GJ.

Am J Cancer Res. 2017 Apr 1;7(4):816-830. eCollection 2017.

27.

Never let it go: Stopping key mechanisms underlying metastasis to fight pancreatic cancer.

Giovannetti E, van der Borden CL, Frampton AE, Ali A, Firuzi O, Peters GJ.

Semin Cancer Biol. 2017 Jun;44:43-59. doi: 10.1016/j.semcancer.2017.04.006. Epub 2017 Apr 22. Review.

28.

Erratum to: Glutamate and α-ketoglutarate: key players in glioma metabolism.

Maus A, Peters GJ.

Amino Acids. 2017 Jun;49(6):1143. doi: 10.1007/s00726-017-2414-5. No abstract available.

PMID:
28417224
29.

The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures.

Narayan RS, Fedrigo CA, Brands E, Dik R, Stalpers LJ, Baumert BG, Slotman BJ, Westerman BA, Peters GJ, Sminia P.

BMC Cancer. 2017 Mar 21;17(1):204. doi: 10.1186/s12885-017-3193-9.

30.

Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer.

Massihnia D, Avan A, Funel N, Maftouh M, van Krieken A, Granchi C, Raktoe R, Boggi U, Aicher B, Minutolo F, Russo A, Leon LG, Peters GJ, Giovannetti E.

J Hematol Oncol. 2017 Jan 6;10(1):9. doi: 10.1186/s13045-016-0371-1.

31.

Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer.

Van Der Steen N, Deben C, Deschoolmeester V, Wouters A, Lardon F, Rolfo C, Germonpré P, Giovannetti E, Peters GJ, Pauwels P.

World J Clin Oncol. 2016 Dec 10;7(6):425-432. doi: 10.5306/wjco.v7.i6.425.

32.

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Chemotherapy: A Glimmer of Hope?

Van Der Steen N, Rolfo CD, Pauwels P, Peters GJ, Giovannetti E.

J Clin Oncol. 2017 Feb 20;35(6):692-693. doi: 10.1200/JCO.2016.70.1987. Epub 2016 Dec 5. No abstract available.

PMID:
27918717
33.

A specific inhibitor of lactate dehydrogenase overcame the resistance toward gemcitabine in hypoxic mesothelioma cells, and modulated the expression of the human equilibrative transporter-1.

Giovannetti E, Leon LG, Gómez VE, Zucali PA, Minutolo F, Peters GJ.

Nucleosides Nucleotides Nucleic Acids. 2016 Dec;35(10-12):643-651.

PMID:
27906635
34.

Role of genomic factors beyond thymidylate synthase in the prediction of response to 5-fluorouracil.

Peters GJ, Smid K, Meijer E, van Groeningen CJ, Leon LG.

Nucleosides Nucleotides Nucleic Acids. 2016 Dec;35(10-12):595-603.

PMID:
27906628
35.

Advances in purine and pyrimidine metabolism in health and diseases.

Hirano M, Peters GJ.

Nucleosides Nucleotides Nucleic Acids. 2016 Dec;35(10-12):495-501.

36.
37.

The radiosensitizing effect of fluorocyclopentenyl-cytosine (RX-3117) in ovarian and lung cancer cell lines.

Sarkisjan D, van den Berg J, Smit E, Lee YB, Kim DJ, Peters GJ.

Nucleosides Nucleotides Nucleic Acids. 2016 Dec;35(10-12):619-630.

PMID:
27906620
38.

Efficacy of thioguanine treatment in inflammatory bowel disease: A systematic review.

Meijer B, Mulder CJ, Peters GJ, van Bodegraven AA, de Boer NK.

World J Gastroenterol. 2016 Oct 28;22(40):9012-9021. Review.

39.

hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients.

Meijer LL, Puik JR, Peters GJ, Kazemier G, Giovannetti E.

Oncologist. 2016 Dec;21(12):e4. Epub 2016 Nov 2. No abstract available.

40.

New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?

Van Der Steen N, Caparello C, Rolfo C, Pauwels P, Peters GJ, Giovannetti E.

Onco Targets Ther. 2016 Oct 6;9:6065-6074. eCollection 2016. Review.

41.

Role of Akt signaling in resistance to DNA-targeted therapy.

Avan A, Narayan R, Giovannetti E, Peters GJ.

World J Clin Oncol. 2016 Oct 10;7(5):352-369. Review.

42.

Glutamate and α-ketoglutarate: key players in glioma metabolism.

Maus A, Peters GJ.

Amino Acids. 2017 Jan;49(1):21-32. doi: 10.1007/s00726-016-2342-9. Epub 2016 Oct 17. Review. Erratum in: Amino Acids. 2017 Jun;49(6):1143.

43.

Adherence and Patients' Experiences with the Use of Capecitabine in Daily Practice.

Timmers L, Boons CC, Mangnus D, Van de Ven PM, Van den Berg PH, Beeker A, Swart EL, Honeywell RJ, Peters GJ, Boven E, Hugtenburg JG.

Front Pharmacol. 2016 Sep 21;7:310. eCollection 2016.

44.

P2.09: cMET in NSCLC: Expression, Amplification and Mutations: Track: Biology and Pathogenesis.

Van Der Steen N, Rolfo C, Giovannetti E, Reclusa P, Peters GJ, Pauwels P.

J Thorac Oncol. 2016 Oct;11(10S):S221-S222. doi: 10.1016/j.jtho.2016.08.083. Epub 2016 Sep 22. No abstract available.

45.

Folates as adjuvants to anticancer agents: Chemical rationale and mechanism of action.

Danenberg PV, Gustavsson B, Johnston P, Lindberg P, Moser R, Odin E, Peters GJ, Petrelli N.

Crit Rev Oncol Hematol. 2016 Oct;106:118-31. doi: 10.1016/j.critrevonc.2016.08.001. Epub 2016 Aug 9. Review.

46.

The Cytidine Analog Fluorocyclopentenylcytosine (RX-3117) Is Activated by Uridine-Cytidine Kinase 2.

Sarkisjan D, Julsing JR, Smid K, de Klerk D, van Kuilenburg AB, Meinsma R, Lee YB, Kim DJ, Peters GJ.

PLoS One. 2016 Sep 9;11(9):e0162901. doi: 10.1371/journal.pone.0162901. eCollection 2016.

47.

FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer.

Caparello C, Meijer LL, Garajova I, Falcone A, Le Large TY, Funel N, Kazemier G, Peters GJ, Vasile E, Giovannetti E.

World J Gastroenterol. 2016 Aug 21;22(31):6987-7005. doi: 10.3748/wjg.v22.i31.6987. Review.

48.

Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth.

Rovithi M, de Haas RR, Honeywell RJ, Poel D, Peters GJ, Griffioen AW, Verheul HM.

J Exp Clin Cancer Res. 2016 Sep 7;35(1):138. doi: 10.1186/s13046-016-0411-2.

49.

cMET Exon 14 Skipping: From the Structure to the Clinic.

Van Der Steen N, Giovannetti E, Pauwels P, Peters GJ, Hong DS, Cappuzzo F, Hirsch FR, Rolfo C.

J Thorac Oncol. 2016 Sep;11(9):1423-32. doi: 10.1016/j.jtho.2016.05.005. Epub 2016 May 17. Review.

50.

All models are wrong, but some are useful: a comment on Ogden (2016).

Peters GJ, Kok G.

Health Psychol Rev. 2016 Sep;10(3):265-8. doi: 10.1080/17437199.2016.1190658. No abstract available.

PMID:
27216695

Supplemental Content

Loading ...
Support Center